nach oben

Erschienen in:

01.05.2005 | Brief Report

Cerebral aspergillosis in the critically ill: two cases of successful medical treatment

verfasst von: Stephan Ehrmann, Frédéric Bastides, Valérie Gissot, Emmanuelle Mercier, Pascal Magro, Eric Bailly, Annick Legras

Erschienen in: Intensive Care Medicine | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

Objective

Invasive aspergillosis is associated with a poor prognosis, especially in critically ill patients with cerebral involvement. We present two cases of cerebral invasive aspergillosis successfully treated in the intensive care unit with combination antifungal therapies and without surgery.

Case presentation

The first patient was a 49-year-old man with rheumatoid arthritis who received corticosteroid and cyclophosphamide treatment and developed pulmonary and cerebral invasive aspergillosis. After failure of voriconazole the patient had a successful outcome with voriconazole and liposomal amphotericin B therapy. The patient returned home after an 8-month hospital stay. The second patient was a 54-year-old woman with pulmonary neoplasia and corticosteroid treatment who developed pulmonary and cerebral invasive aspergillosis. After failure of voriconazole and liposomal amphotericin B therapy the patient had a favorable outcome with liposomal amphotericin B and caspofungin therapy. The patient died 10 months after initial diagnosis of cardiac tamponade unrelated to fungal infection.

Discussions

These cases illustrate the improving prognosis of invasive aspergillosis due to the availability of new treatments, especially in cases of cerebral involvement. It also demonstrates that the outcome of critically ill patients requiring mechanical ventilation for invasive aspergillosis can be favorable. The treatment of patients with invasive cerebral aspergillosis in the intensive care setting should be encouraged.

Steinbach WJ, Stevens DA, Denning DW (2003) Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 37 [Suppl 3]:S188–S224

Schwartz S, Thiel E (2004) Update on the treatment of cerebral aspergillosis. Ann Hematol 83 [Suppl 1]:S42–S44

Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D (2004) Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect 56:269–276

Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E (2004) Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 170:621–625

Guermazi A, Gluckman E, Tabti B, Miaux Y (2003) Invasive central nervous system aspergillosis in bone marrow transplantation recipients: an overview. Eur Radiol 13:377–388CrossRefPubMed

Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571CrossRefPubMed

Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415CrossRefPubMed

Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ, Caspofungin Salvage Aspergillosis Study Group (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563–1571

Damaj G, Ivanov V, Le Brigand B, D’Incan E, Doglio MF, Bilger K, Faucher C, Vey N, Gastaut JA (2004) Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient. Ann Hematol 83:390–393

10.

Schwartz S, Milatovic D, Thiel E (1997) Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 97:663–665

11.

Lastours V de, Lefort A, Zappa M, Dufour V, Belmatoug N, Fantin B (2003) Two cases of cerebral aspergillosis successfully treated with voriconazole. Eur J Clin Microbiol Infect Dis 22:297–299

12.

Marbello L, Nosari A, Carrafiello G, Anghilieri M, Cesana C, Cafro AM, D’Avanzo G, Morra E (2003) Successful treatment with voriconazole of cerebral aspergillosis in an hematologic patient. Haematologica 88:ECR05

13.

Vandewoude K, Vogelaers D, Decruyenaere J, Jaqmin P, De Beule K, Van Peer A, Woestenborghs R, Groen K, Colardyn F (1997) Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 41:2714–2718

14.

Sanchez C, Mauri E, Dalmau D, Quintana S, Aparicio A, Garau J (1995) Treatment of cerebral aspergillosis with itraconazole: do high doses improve the prognosis? Clin Infect Dis 21:1485–1487

15.

Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, Piscitelli SC, Walsh TJ (2000) Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 182:274–282

16.

Baslar Z, Soysal T, Hanci M, Aygun G, Ferhanoglu B, Sarioglu AC, Ulku B (1998) Successfully treated invasive central nervous system aspergillosis in an allogeneic stem cell transplant recipient. Bone Marrow Transplant 22:404–405

17.

Baslar Z, Soysal T, Hanci M, Aygun G, Ferhanoglu B, Sarioglu AC, Ulku B (1997) Successful outcome of aspergillus brain abscess in a patient who underwent bone marrow transplantation for aplastic anemia. Haematologia (Budap) 28:265–271

18.

Iemmolo RM, Rossanese A, Rotilio A, Mattisi G, Gerunda GE, Merenda R, Neri D, Crepaldi G, Strazzabosco M (1998) Cerebral aspergillosis in a liver transplant recipient: a case report of long-term survival after combined treatment with liposomal amphotericin B and surgery. J Hepatol 28:518–522

19.

Roy V, Ali LI, Carter TH, Selby GB (2000) Successful non-surgical treatment of disseminated polymicrobial fungal infection in a patient with pancytopenia and graft-versus-host disease. J Infect 41:273–275

20.

Carlini A, Angelini D, Burrows L, De Quirico G, Antonelli A (1998) Cerebral aspergillosis: long term efficacy and safety of liposomal amphotericin B in kidney transplant. Nephrol Dial Transplant 13:2659–2661

Titel: Cerebral aspergillosis in the critically ill: two cases of successful medical treatment
verfasst von: Stephan Ehrmann
Frédéric Bastides
Valérie Gissot
Emmanuelle Mercier
Pascal Magro
Eric Bailly
Annick Legras
Publikationsdatum: 01.05.2005
Verlag: Springer-Verlag
Erschienen in: Intensive Care Medicine / Ausgabe 5/2005
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-005-2605-5

Neu im Fachgebiet AINS

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Cerebral aspergillosis in the critically ill: two cases of successful medical treatment